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CYTOKINES and their receptors are involved in the
pathophysiology of many diseases. Here we pre-
sent a detailed review on cytokines, receptors and
signalling routes, and show that one important
lesson from cytokine biology is the complex and
diverse regulation of cytokine activity. The activ-
ity of cytokines is controlled at the level of trans-
cription, translation, storage, processing, post-
translational modification, trapping, binding by
soluble proteins, and receptor number and/or
function. Translation of this diverse regulation in
strategies aimed at the control of cytokine activity
will result in the development of more specific
and selective drugs to treat diseases.
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Introduction
For over two decades, it has been recognized
that immune-competent cells produce peptide
mediators, now termed cytokines. Cytokines act
as chemical communicators between cells, but
mostly not as effector molecules in their own
right. The biological function of many cytokines
is mediated through their ability to regulate
gene expression in target cells. Recent develop-
ments have made it clear that cytokines play
crucial roles in the regulation of normal growth
and development, protection against inflamma-
tion and infection, neoplastic transformation,
wound-healing and angiogenesis. For example,
inflammatory mediators are involved in the
pathophysiology of septic shock and they are
often associated with disease severity. In such
diseases the balance between pro-inflammatory
cytokines (interleukin-1 (IL-1), IL-6, IL-8, tumour
necrosis factor-alpha (TNF<z)) and anti-inflam-
matory compounds (IL-1 receptor antagonist
(IL-lra), IL-IO, soluble IL-1 receptor (slL-1R),
sTNFR) determines to a large extent the final
outcome. Also, in many diseases it was shown
that production levels or activity of important
cytokines is perturbed. Understanding the con-
trol of cytokine activity is therefore important
as it may provide new potential strategies to
treat diseases.
In general, cytokines are not expressed con-
stitutively, but are rapidly produced after stimu-
lation and act locally to restore homeostasis.
Cytokines bind with high affinity to specific
receptors on the surface of target cells. When
cytokine receptors are expressed on the cyto-
kine-producing cell, autocrine cellular activation
may be the result. If the receptor is expressed
on a neighbouring cell, binding may result in
paracrine cytokine activation. These features
could explain the sometimes high local concen-
tration and profound local effects of cytokines.
A characteristic feature of cytokines is their
functional pleiotropy (cytokines result in di-
verse effects upon binding to different target
cells) and redundancy (several cytokines can
take over each other’s effects), which can be
largely explained at the molecular level of
receptor systems (see below).
Families of Cytokines
Table 1 presents a scheme in which cytokines
are grouped according to their three-dimen-
sional structure and receptor usage.2-4 This
scheme is still incomplete and inconclusive. At
least six different families of cytokines have
been identified: the haemopoietins (four
-
helical bundles); IL-1 and fibroblast growth
factor (FGF) (capped [3-barrel of 12 antiparallel
[3-strands); TNF (sandwich of antiparallel
-
sheets in jelly roll motif); transforming growth
factor-alpha (TGF<z) and epidermal growth fac-
tor (EGF) (-sheets); TGF-, platelet-derived
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Table 1. Structural families of cytokines and their receptors
Families of cytokines Members Superfamilies (SF) of cytokine
receptors
Haemopoietins
IL-1
TNF
TGF-z
TGF-13
Chemokines
subfamily
subfamily
IL-6, IL-11, LIF, OM, CNTF, CT-1
IL-3, IL-5, GM-CSF
IL-2, IL-4, IL-7, IL-9, IL-13, IL-15
IL-10, IFN-, IFN-I, IFN-y
M-CSF
IL-lcz, IL-113, IL-lra, FGF-(z, FGF-I
TNF-ot, TNF-I, LT-I
TGF-(z, EGF
TGF-II, TGF-132, TGF-I3
PDGF, VEGF
NGF
IL-8, GRO-(z, GRO-I, GRO-y, ENA-78, IP-10, MIG, GCP-2,
PBP (and its cleavage products: CTAP-III,
thromboglobulin, NAP-2), PF-4, SDF-I(z, SDF-113
MCP-1, MCP-2, MCP-3, RANTES, 1-309, MIP-I, MIP-113
Cytokine receptor SF class
gp130
common 13-chain
common y-chain
Cytokine receptor SF class II
Immunoglobulin SF
Immunoglobulin SF
TNF receptor SF
Protein tyrosine kinase receptor SF
TGF-13 receptors
Immunoglobulin SF
TNF receptor SF
Chemokine receptor SF
aThe families of cytokines are named after a representative member (except for the haemopoietins and chemokines).
bThe family of haemopoietins also comprise G-CSF and erythropoietin (Epo), but data on their receptors are insufficient for receptor
classification.
CTo date, the TGF-I receptors are not grouped into a SF of cytokine receptors.
dAbbreviations (apart from those explained in the text): CTAP, connective tissue activating protein; ENA, epithelial-derived neutrophil
attractant; GCP, granulocyte chemotactic protein; IP, IFN-T-inducible protein; LT, lymphotoxin; MIG, manokine induced by IFN-y: MIP,
macrophage inflammatory protein" NAP, neutrophil-activating peptide; PBP, platelet basic protein; PF, platelet factor; RANTES, regulated on
activation, normal T-cell expressed and secreted; SDF, stromal cell-derived factor.
growth factor (PDGF), vascular endothelial
growth factor (VEGF) and nerve growth factor
(NGF) (cysteine knots); and chemotactic cyto-
kines (chemokines) (triple-stranded, anti-parallel
]3-sheets in Greek key motiO.2-4 The large family
of chemokines can be subdivided into at least c-
chemokines (the two most amino-proximal
cysteine residues are separated by an interven-
ing amino acid: CXC) and [3-chemokines (CC),
which are functionally distinct, as they predomi-
nantly attract neutrophils and monocytes,
5
respectively. It is intriguing that different struc-
tural domains of cytokines (e.g. IL-I[3) may
display different or even antagonistic cytokine
activities.6
Families of Cytokine Receptors
Cytokine receptors are classified into several
superfamilies based on common homology re-
gions. The main superfamilies recognized today
are the cytokine receptor superfamilies class I
and class II, the immunoglobulin superfamily,
the TNF receptor superfamily, the protein ty-
rosine kinase receptor superfamily, and the
chemokine receptor superfamily. Figure 1 illus-
trates schematically these cytokine receptor
superfamilies. It should be noted that the super-
families are not restricted to cytokine receptors
(for example, several hormone receptors and
leukocyte membrane polypeptides also belong
to cytokine receptor superfamilies) and several
cytokine receptors belong to more than one
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superfamily (e.g. IL-6 receptor belongs to both
the class I receptor and immunoglobulin super-
families). All cytokine receptors are single
transmembrane proteins, except for the chemo-
kine receptors which contain seven transmem-
brane domains.
The cytokine receptor superfamily class I
receptors are characterized by the presence of
combinations of cytokine and fibronectin III
domains in the extracellular regions. The amino
terminal cytokine domain(s) contains four con-
served cysteine residues, and (one of) the
membrane proximal fibronectin III domains
contains the Trp-Ser-X-Trp-Ser (WSXWS) motif
required for ligand binding.7 Functional class I
receptors consist of a complex of two or three
receptor chains. These multisubunit receptors
can be grouped according to the identity of
common chains which are required for high
affinity ligand binding and signal transduction.
Three subgroups of class I receptors were
identified sharing either gpl30 (a glycoprotein
with a relative molecular mass (Mr) of 130 kDa,
cluster of differentiation (CD) 130), the com-
mon
-chain (Mr: 120 kDa, KH97) or the com-
mon ,-chain (Mr: 64-kDa) (see Table 1 and Fig.
1). The gp130 chain is shared by the receptors.
for IL-6, IL-11, ciliary neurotrophic factor
(CNTF), leukaemia inhibitory factor (LIF), on-
costatin M (OM) and cardiotrophin-1 (CT-1).9
Ligand binding by this group of receptors
induces homodimerization of gpl30 (in case of
IL-6R and IL-11R) or heterodimerization of
Cytokines as communicators
Cytokine receptor SF class
Cytokine receptor SF class
common
Immunoglobulin SF TNF receptor SF
,.),JNF (homotrimer)
Chemokine receptor SF
-eprobtnn-bund.
FIG. 1. Superfamilies of cytokine receptors. Examples are depicted, containing a representative cytokine bound to its
receptor. Note that signalling through the IL-6 receptor complex is preceded by gp130 homodimerization, and that IL-1
receptor signalling is characterized by a cascade of protein phosphorylation. For simplicity reasons, the protein tyrosine
kinase receptor SF is not shown, as it only covers the interaction with the growth factors TGF-c and EGF. Abbreviations are
explained in the text and Table 1.
gp130 and LIFR (in case of CNTFR). LIE OM
and CT-1 are believed to directly induce hetero-
dimerization of gpl30 and LIFR (OM and
perhaps CT-1 also induce heterodimerization of
gpl30 and the ligand-specific receptor). The
LIFR, granulocyte-colony stimulating factor (G-
CSF) R and IL-12R are highly homologous with
gpl30 and belong to the so-called gp130 family.
The common
-chain is shared by IL-3R, IL-5R
and granulocyte and macrophage-CSF (GM-CSF)
R, whereas the common y-chain is shared by IL-
2R, IL-4R, IL-7R, IL-9R, IL-13R and IL-15R.
Recent evidence suggests that the cytoplasmic
parts of these signal transducing chains harbour
two functional domains: a membrane-proximal
region which is essential for proliferation signals
(c-myc induction), and a membrane-distal region
which is essential for differentiation signals (c-
101los and c-jun induction).’ The signalling
routes which result from activation of the
common chains are discussed below.
The cytokine receptor superfamily class II
receptors (interferon (IFN) R and IL-IOR) con-
tain one or two extracellular fibronectin III
domains, which lack the WSXWS motif charac-
teristic of the class I receptors7 Ligand binding
may induce receptor homodimerization (e.g.
IFN-yR) and activate the Janus kinases OAK)-
signal transducers and activators of transcrip-
tion (STAT) pathway (see below). The immuno-
globulin superfamily receptors (IL-1R, IL-6R,
FGFR, M-CSFR, PDGFR, VEGFR, stem cell factor
R (SCFR)) contain one or more domains with
the characteristic immunoglobulin fold.12 Recep-
tors belonging to the protein tyrosine kinase
receptor superfamily (EGFR, insulin-like growth
Mediators of Inflammation Vol 5 1996 419
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factor (IGF) R, FGFR, M-CSFR, PDGFR, VEGFR, Table2. Selective usage of JAK kinases and STAT factors
SCFR) are in general growth factor receptors by cytokine receptors
with an intracellular tyrosine kinase catalytic Receptor JAKkinases STATfactors
domain.13 Ligand binding by these receptors
IL-2induces receptor homo- or oligomerization, IL-3
autophosphorylation and subsequent signalling.
Members of the TNF receptor superfamily
(TNFR and NGFR) are characterized by three or
four cysteine-rich repeats in the extracellular
part of the molecule.14 These receptors may
bind more than one ligand. Little is known
about the mode of signal transduction by
receptors of this superfamily. Receptors of the
L-4
L-5
L-6
L-7
L-9
L-10
L-11
L-12
L-13
L-15
FN-c/Ichemokine receptor superfamily are coupled to FNq,
guanosine triphosphate (GTP) binding proteins G-CSF
which, after ligand binding, activate lipases, GM-CSF
CNTF5kinases, phosphatases and ion channels OM
LIF
Cytokine Receptor Signalling
1,3
1,2
1,3
1,2
1, 2, Tyk2
1,3
1,3
1, Tyk2
1, 2, Tyk2
2, Tyk2
not known
1,3
1, Tyk2
1,2
2
1,2
1, 2, Tyk2
1, 2, Tyk2
1, 2, Tyk2
3,5
5
6
5
1,3
5
3
1,3
not known
3,4
6
5
1,2,3
not known
5
3
3
3
aModified from Refs 16, 17 and Schreiber RD, oral presentation,
cytokine meeting, 6-10 October 1996, Geneva, Switzerland.
Recent studies have demonstrated that the
cytoplasmic domains of cytokine receptors are cytokine genes distinct combinations of these
critical for signal transduction. Ligand-induced transcription factors determine the transcrip-
receptor di-or oligomerization typically results tional activity of these loci. Activation of the
in activation of (receptor-associated) protein individual cytokine genes requires binding of
tyrosine kinases (such as members of the SRC distinct sets of transcription factors. The data
kinases OAK)) which are associated with the on the involvement of the JAK/STAT pathway
cytoplasmic tails of cytokine receptors. Subse- do not preclude that the activation of these
quently, activated JAK1 are thought to phos- genes may be secondary to the activation of the
phorylate several substrates (such as the above mentioned combination of transcription
receptors themselves, members of the RAS- factors.
mitogen activated protein (MAP) kinase cas-
cades, and transcription factors). Phosphoryla-
tion of tyrosine-based motifs in the cytoplasmic Soluble Cytokine Receptorsdomains of the receptors is followed by specific
docking and activation of members of the STAT It seems that essentially all single transmem-
family of proteins.15’16 Activated STATs form brane cytokine receptors exist as soluble
homodimers, translocate into the nucleus, and forms.19 Soluble receptors can be translated
bind to specific responsive elements to initiate from differentially spliced pre-mRNA molecules
gene transcription. This JAK-STAT pathway re- lacking the transmembrane domain (e.g. IL-4R,
suits in rapid and specific transcriptional IL-5R, IL-6R, IL-7R, IL-9R, GM-CSFR, G-CSFR,
activation of target genes, and may, at least in TGF-cR). However, the presence of mRNA for
part, contribute to cytokine-specific responses soluble receptors not always seems to represent
through selective activation of individual JAK protein synthesis. Soluble receptors can also be
kinases (JAK1, JAK2, JAK3 and TYK2)and STAT generated by proteolysis of cell surface recep-
factors (STAT1 through STAT6).7’18 Table 2 tors (e.g. IL-1R, IL-2Rcz, IL-6R, gpl30, PDGFR,
presents more details on receptor-mediated NGFR, TNFR, TGF-R) and by phospholipase
activation of induced JAK kinases and STAT action on the glycosyl-phosphatidylinositol
factors for various cytokine receptors. Besides (GPI) anchor of CNTFR. Proteolytic shedding
this tyrosine kinase pathway, also the serine may be controlled by protein kinase C and may
kinase pathway is involved in cytokine-receptor involve a metalloprotease, since phorbol myris-
mediated signalling. In activated T-cells the tate acetate (PMA)-induced shedding of IL-6R,
activation of transcription factors, like activating TNFR type I and II as well as membrane TNF-(z
protein-1 (AP-1) (fos/jun dimers), members of is blocked by a metalloprotease inhibitor, which
the nuclear factor in activated T cells (NF-AT) was first identified as TNF-0t protease inhibitor
family and NF-KB, play distinct roles in the (TAPI).2’2] Soluble cytokine receptors are found
induced differentiation. In the promotors of in appreciable amounts in body fluids, although
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the exact cellular source and function of these
proteins is not completely clear.
Virokines
The immunological relevance of cytokines and
(soluble) cytokine receptors is clearly illustrated
by the observation that several pathogenic virus
strains, particularly pox viruses, encode pro-
teins which counteract the anti-viral cytokine
activity during the host response.22 Examples of
these so-called virokines include a homologue
of the host suppressive cytokine IL-10 encoded
by Epstein-Barr virus2 and several poxviral
homologues of soluble IL-1R (sIL-1R), sTNFR
and sIFNR, which prevent interaction of the
ligands with cellular receptors.2z’z4 In addition,
herpes viruses and cytomegalovirus encode
chemokine receptors which are expressed on
the membrane of infected cells, but probably
display an altered function.2 Furthermore, intra-
cellular viral proteins have been described that
interfere with cytokine maturation and cyto-
kine-mediated responses.22
Cytokine Biology
The current view on cytokine biology is that of
a network of cytokines with additive, synergistic
and opposite effects, and inducers and inhibi-
tors of the expression of cytokines and/or their
receptors, which combine to give an overall
biological (or clinical) response.26 Cytokines are
potent molecules, of which the activity is
regulated at multiple levels.
First, stimuli are required to induce as well as
to suppress the transcription of most cytokine
genes. For example, infectious or toxic agents,
mechanical injury, inflammatory mediators, and
cytokines themselves (e.g. IL-1, TNE IFN-y) are
potent cytokine inducers, whereas glucocorti-
coids, prostaglandins and cytokines (e.g. IL-10
anti-cytokine (auto)antibodies
soluble cytokine receptors
natural or pharmacological antagonists
functionally active cytokine
ICE inhibitors
processing
tokine receptor
hibit
variant
transnA_elnCSAIDs
ransorlptlo,AraioSz/rSeesnucleot.de
inCiindeSs
FIG. 2. Schematic outline of a target cell (represented only by a plasma and a nuclear membrane) illustrating the synthesis
and activation of cytokines and cytokine receptors. At multiple sites interference can potentially lead to inhibition of
production and/or activation of cytokines and their receptors. Numerous drugs have been reported which interfere with
cytokine, receptor synthesis or activation. Those mentioned in the figure, therefore, merely serve as an example.
Abbreviations (apart from those explained in the text): CSAID, cytokine synthesis anti-inflammatory drug; ICE, interleukin-ll
converting enzyme.
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and TGF-[3) are potent inhibitors of cytokine
gene expression. Note that genetic polymorph-
isms (e.g. IL-lc, IL-lra and TNF-27-29) may
contribute to interindividual differences in cyto-
kine expression upon stimulation.
Second, the extent of cytokine protein pro-
duction is limited, since the consensus se-
quence UUAUUUAU in the 3’ end of most
cytokine mRNAs promotes message instability.5
Translation of cytokine mRNA transcripts may,
in addition to the first signal, require an
additional signal (e.g. in the case of IL-I).31
Third, several cytokines are not released
through the classic secretory pathway. These
cytokines are produced as larger biologically
inactive precursor molecules, which are stored
within the cytoplasm (e.g. IL-1, IL-8, GM-CSF,
TGF-[3, PDGF) or expressed on the plasma
membrane (e.g. TGF-c, IL-lc, TNF-cO, and need
to be proteolytically cleaved to release the
mature molecule (e.g. TGF-{x, IL-Iz, IL-I, TNF-
cz).2-4 Extracellular enzymes may also contri-
bute to the processing of precursor molecules
(e.g. IL-I, TGF-).5,6
Fourth, post-translational modifications (e.g.
cleavage-site of leader peptide, glycosylation,
phosphorylation and/or multimerization) affect
the biological activity of mature cytokines (e.g.
It-6, It-8).37-39
Fifth, once secreted, several cytokines are
trapped by cell surface binding proteins (e.g.
TGF-), extracellular matrix (e.g. LIE IL-1, FGF),
stromal cells (e.g. IL-3, IL-5, GM-CSF) and
endothelial cells (e.g. IL-8).3’4 It should be
noted that the intracellular, membrane and
extracellular pools of cytokines are available for
rapid maturation and/or release in response to
stimulation.
Sixth, soluble proteins which bind to cyto-
kines can potentiate or antagonize cytokine
activity. The proteins bind to cytokines either
nonspecifically such as 2-macroglobulin41 or
specifically such as autoantibodies to cytokines
(e.g. IL-I, IL-6, IL-8, IL-IO, monocyte chemo-
tactic protein-1 (MCP-1), IFN-x)42,4 and soluble
cytokine receptors.19 So far all known soluble
forms of cytokine receptors were found to
retain their ligand binding capacity. On the one
hand, these soluble proteins may agonize cyto-
kine activity by acting as chaperons, increasing
4,44the cytokine’s persistence.’ Moreover, in case
of slL-6R and sCNTFR, the soluble proteins form
a biologically active binary complex with their
ligands (IL-6msIL-6R, CNTFmsCNTFR) which
may act on cells only expressing gp130 on their
cell surface, but not IL-6R or CNTFR (normally
anticipated as cells being unresponsive to IL-6
or CNTF).19 Note that in line with this ’trans-
signalling pathway’ is the fact that gp130 is
present essentially on all cell types, whereas IL-
6R and CNTFR are not expressed ubiquitously.
On the other hand, soluble proteins may
antagonize cytokine activity by acting as scaven-
gers of cytokines (by competing with mem-
brane receptors), by neutralizing their activity,
by enhancing antibody-dependent cell-mediated
cytotoxicity, by preventing extravascular escape
and by promoting excretion.4 Whether soluble
proteins will act as agonists or antagonists of
cytokine activity is, at least in part, determined
by the ratio between membrane receptors and
soluble proteins: the predominance of mem-
brane receptors favours agonistic activity,
whereas the predominance of soluble proteins
favours antagonistic activity.44
Finally, cytokine activity can be regulated by
modulating the number and/or function of
membrane receptors. Receptor number may be
modulated by controlling gene expression, in-
ternalization or the generation of soluble recep-
tors. Receptor affinity and/or function may be
modulated by affecting receptor phosphoryla-
tion and/or glycosylation, by competition for
common receptor chains or signal transduction
molecules16’41 or by binding cytokine receptor
antagonists. These latter molecules bind to the
receptor but do not cause signal transduction
(for example, IL-lra, IL-462 and (p40)2 antag-
onize IL-1, IL-4 and IL-12 functions, respec-
tively).45-47
Strategies aiming at controlling cytokine activ-
ity take this into account and are schematically
illustrated in Fig. 2.
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